A pilot safety and tolerability study of scanning ultrasound as a neuromodulation therapy in Alzheimer's disease.

ABSTRACT: Clearing amyloid-β pathology in Alzheimer's disease (AD) has been considered a prerequisite for restoring cognitive functions. Intriguingly, by application of a modality of scanning ultrasound (SUS) to mice that does not remove amyloid-β, we previously achieved significant cognitive improvements. This prompted us to explore SUS as a non-invasive brain stimulation strategy in an open-label safety trial in AD. We conducted a human pilot study in 12 participants with AD with the primary objective of determining feasibility, safety and tolerability. Exploratory secondary end-points were cognitive and behavioural measures, resting-state EEG and functional MRI. A portable device termed UltraThera^Pilot was built under medical device standard guidelines, integrating a Brainsight image-g

SUBMITTER: Nestor PJ 

PROVIDER: S-EPMC12703879 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature